Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A‐kinase‐interacting protein 1 facilitates growth and metastasis of gastric cancer cells via Slug‐induced epithelial‐mesenchymal transition

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A‐kinase‐interacting protein 1 (AKIP1) has previously been reported to act as a potential oncogenic protein in various cancers. The clinical significance and biological role of AKIP1 in gastric cancer (GC) is, however, still elusive. Herein, this study aimed to investigate the functional and molecular mechanism by which AKIP1 influences GC. AKIP1 mRNA and protein expressions in GC tissues were examined by quantitative real‐time PCR (qRT‐PCR), Western blot and immunohistochemistry. Other methods including stably transfected against AKIP1 into gastric cancer cells, wound healing, transwell assays, CCK‐8, colony formation, qRT‐PCR and Western blot in vitro and tumorigenesis in vivo were also performed. The up‐regulated expression of AKIP1 in GC specimens significantly correlated with clinical metastasis and poor prognosis in patients with GC. AKIP1 knockdown markedly suppressed GC cells proliferation, invasion and metastasis both in vitro and in vivo. In contrast, AKIP1 overexpression resulted in the opposite effects. Moreover, mechanistic analyses indicated that Slug‐induced epithelial‐mesenchymal transition (EMT) might be responsible for AKIP1‐influenced GC cells behaviour. Our findings demonstrated that high AKIP1 expression significantly correlated with clinical metastasis and unfavourable prognosis in patients with GC. Additionally, AKIP1 promoted GC cells proliferation, migration and invasion by activating Slug‐induced EMT.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: not found
          • Article: not found

          EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Targeting EMT in cancer: opportunities for pharmacological intervention.

            The spread of cancer cells to distant organs represents a major clinical challenge in the treatment of cancer. Epithelial-mesenchymal transition (EMT) has emerged as a key regulator of metastasis in some cancers by conferring an invasive phenotype. As well as facilitating metastasis, EMT is thought to generate cancer stem cells and contribute to therapy resistance. Therefore, the EMT pathway is of great therapeutic interest in the treatment of cancer and could be targeted either to prevent tumor dissemination in patients at high risk of developing metastatic lesions or to eradicate existing metastatic cancer cells in patients with more advanced disease. In this review, we discuss approaches for the design of EMT-based therapies in cancer, summarize evidence for some of the proposed EMT targets, and review the potential advantages and pitfalls of each approach.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Molecular targeted therapy for the treatment of gastric cancer

              Despite the global decline in the incidence and mortality of gastric cancer, it remains one of the most common malignant tumors of the digestive system. Although surgical resection is the preferred treatment for gastric cancer, chemotherapy is the preferred treatment for recurrent and advanced gastric cancer patients who are not candidates for reoperation. The short overall survival and lack of a standard chemotherapy regimen make it important to identify novel treatment modalities for gastric cancer. Within the field of tumor biology, molecular targeted therapy has attracted substantial attention to improve the specificity of anti-cancer efficacy and significantly reduce non-selective resistance and toxicity. Multiple clinical studies have confirmed that molecular targeted therapy acts on various mechanisms of gastric cancer, such as the regulation of epidermal growth factor, angiogenesis, immuno-checkpoint blockade, the cell cycle, cell apoptosis, key enzymes, c-Met, mTOR signaling and insulin-like growth factor receptors, to exert a stronger anti-tumor effect. An in-depth understanding of the mechanisms that underlie molecular targeted therapies will provide new insights into gastric cancer treatment.
                Bookmark

                Author and article information

                Contributors
                dr_liuqinghong@163.com
                Journal
                J Cell Mol Med
                J. Cell. Mol. Med
                10.1111/(ISSN)1582-4934
                JCMM
                Journal of Cellular and Molecular Medicine
                John Wiley and Sons Inc. (Hoboken )
                1582-1838
                1582-4934
                24 April 2019
                June 2019
                : 23
                : 6 ( doiID: 10.1111/jcmm.2019.23.issue-6 )
                : 4434-4442
                Affiliations
                [ 1 ] Department of General Surgery Taizhou People's Hospital The Fifth Affiliated Hospital of Nantong University Taizhou China
                Author notes
                [*] [* ] Correspondence

                Qinghong Liu, Department of General Surgery, Taizhou People’s Hospital, The Fifth Affiliated Hospital of Nantong University, No. 366 Taihu Road, Taizhou, Jiangsu, China.

                Email: dr_liuqinghong@ 123456163.com

                Author information
                https://orcid.org/0000-0001-7950-7530
                Article
                JCMM14339
                10.1111/jcmm.14339
                6533465
                31020809
                47f3809e-ece5-4fcd-9e82-ce3fbf9e4983
                © 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 07 September 2018
                : 07 March 2019
                : 01 April 2019
                Page count
                Figures: 6, Tables: 2, Pages: 9, Words: 4476
                Funding
                Funded by: Taizhou Science and Technology Support Plan
                Award ID: TS201732
                Funded by: Science Foundation of Taizhou People's Hospital
                Award ID: ZL201818
                Funded by: Medical Science and Technology Development Foundation of Jiangsu University
                Award ID: JLY20160148
                Award ID: JLY20160149
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                jcmm14339
                June 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.3 mode:remove_FC converted:24.05.2019

                Molecular medicine
                akip1,epithelial‐mensenchymal transition,gastric cancer
                Molecular medicine
                akip1, epithelial‐mensenchymal transition, gastric cancer

                Comments

                Comment on this article